B3GALT5 and inflammatory bowel disease: Indeed, another study, comprising a large sample size (n = 206) and a less heterogeneous UC patient population, shows significant downregulation in the expression of the B3GALT5 gene (2.25-fold, Figure 6B) along with other glycosyltransferase genes as compared to non-IBD controls.42 We next show that IL-22 induces B3GALT5 expression in human IECs by using the HT-29 cell line (colorectal adenocarcinoma).